Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4635 in Japanese patients with advanced solid malignancies
NCT03980821Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imaradenant in malignant solid tumor, sponsored by AstraZeneca. Primary endpoints: Incidence of Adverse event and SAE and Incidence of Dose-limiting toxicity at 25 days. Started Jul 2019; status: completed.
02
Drugs
imaradenant
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03980821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980821.